공시 • Sep 12
Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors
Medincell's General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon. Dr. Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA®, acquired by Johnson & Johnson for $14.6 billion in April 2025. Dr. Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies. Dr. Pascal Touchon, DVM, has over 40 years of international leadership in the biopharmaceutical industry, including key roles at Novartis Oncology and Atara Biotherapeutics and current board positions at Ipsen, CDR-Life, RoslinCT, Catalym and Xylocor. Other members of Medincell’s Board of Directors are Philippe Guy (Chairman) - Former Head of BCG’s Global Health Care Practice and member of BCG’s Worldwide Executive Committee, Christophe Douat - CEO of Medincell, Elisabeth Kogan - CEO of Clexio Bioscience, former SVP at Teva where she led global generic and specialty R&D, Tone Kvåle - CFO of Herantis Pharma, with over 25 years of biotech finance leadership, Virginie Lleu - Senior Partner at WittKieffer, with over 30 years of experience in executive search for the pharmaceutical industry. Sharon Mates co-founded Intra-Cellular Therapies in 2002 with Nobel Laureate Dr. Paul Greengard, building the company on his groundbreaking research into intracellular signaling to pioneer treatments for psychiatric and neurologic disorders. As Co-founder, Chairman and CEO, Dr. Mates led the development of CAPLYTA® (lumateperone), a breakthrough therapy for schizophrenia and bipolar depression, with analysts projecting peak annual sales of up to $5 billion. Under her leadership, the company went public and grew to a market capitalization of over $10 billion before its acquisition by Johnson & Johnson for $14.6 billion in April 2025. Previously, for almost a decade, Dr. Mates served as President of North American Vaccine Inc., where she oversaw the development of pediatric vaccines. She holds a Ph.D. in anatomy and neuroscience and completed her postdoctoral training at Harvard Medical School and Massachusetts General Hospital. In addition to her scientific leadership as a research analyst and investment banker in the life sciences sector, she has co-founded several biotech companies and has sat on several non-profit boards. Dr. Mates was named to Forbes’ “50 Over 50 – Innovation” list in recognition of her lasting impact on neuroscience and biotech innovation. Charles Kunsch is a seasoned life sciences executive and investor with over 30 years of leadership in R&D, venture capital, and biotech innovation. He served as Managing Director at AbbVie Ventures, where he led investments in many high-impact biotech companies including Prevail Therapeutics (acquired by Lilly) and Tidal Therapeutics (acquired by Sanofi) among others. Earlier in his career, he held senior scientific roles at AbbVie, AtheroGenics and Human Genome Sciences. Charles Kunsch holds a Ph.D. in Immunology from Pennsylvania State University College of Medicine and completed postdoctoral training at the Roche Institute of Molecular Biology. He currently serves as a Venture Partner at Dreavent Capital, Vice Chair of the Board at Massachusetts Biomedical Initiatives, Board of Trustees of the Penn State Research Foundation, and is a board member at Captor Therapeutics and Antiverse. Pascal Touchon has 40 years of international experience in the biopharmaceutical industry, holding both operational and strategic leadership positions and serving on the boards of American and European companies. Throughout his career Pascal has been focused on transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence. He is the former Global Head of Strategy and Business Development, as well as the Global Head of Cell & Gene division at Novartis Oncology, where he led the development and global launch of the first approved cell and gene therapy in the U.S and the former CEO and Chairman of the Board at Atara Biotherapeutics. Pascal Touchon currently serves as Independent Director at Ipsen, CDR-Life, and RoslinCT and Operating Partner at Jeito Capital, an investment fund dedicated to biopharmaceutical companies. Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).